Polyvalent immunoglobulins : Part 1: A rapid review - SUPPLEMENT 2

157 p.ill.,1 IMMUNOGLOBULINS ON THE BELGIAN MARKET 3 -- 1.1 OVERVIEW OF IMMUNOGLOBULIN PRODUCTS REGISTERED IN BELGIUM 3 -- 1.2 OVERVIEW OF STOCK RUPTURES SINCE JANUARY 2018 TILL OCTOBER 2019 4 -- 1.3 OVERVIEW OF MARKET WITHDRAWALS SINCE 2008 4 -- 2 EXTRACTION TABLES OF SYSTEMATIC REVIEWS AND RCTS 5 -- 2.1 EXTRACTION TABLE OF MODERATE TO GOOD QUALITY SRS ON SAFETY 5 -- 2.2 EXTRACTION TABLE OF MODERATE TO GOOD QUALITY SRS FOR INDICATIONS REIMBURSED IN BELGIUM 6 -- 2.3 EXTRACTION TABLE OF MODERATE TO GOOD QUALITY SR FOR INDICATIONS COMMONLY RECOGNISED IN OTHER COUNTRIES 22 -- 2.4 EXTRACTION TABLE OF INCLUDED RCTS IN SELECTED INDICATIONS 28 -- 2.5 SYSTEMATIC REVIEWS ON ‘OTHER’ INDICATIONS 49 -- 3 QUALITY ASSESSMENT 73 -- 3.1 SYSTEMATIC REVIEWS 73 -- 3.2 RISK OF BIAS OF THE RCTS 83 -- 4 EXPERT CONSULTATION 104 -- 4.1 ONLINE SURVEY 104 -- 5 ECONOMIC EVALUATION 108 -- 5.1 TEMPLATE TABLE FOR DATA EXTRACTION – ECONOMIC EVALUATIONS 108 -- 5.2 DATA EXTRACTION TABLES – ECONOMIC EVALUATIONS 110 -- 6 INTERNATIONAL COMPARISON 134 -- 6.1 BELGIUM 134 -- 6.1.1 Off-label indications in Belgium 134 -- 6.2 AUSTRALIA 135 -- 6.2.1 – The IG CRITERIA (as published on the website since January 2019) 135 -- 6.2.2 Level of evidence categories used for categorizing and establishing the Ig Criteria 141 -- 6.3 FRANCE 142 -- 6.3.1 Reimbursed indications based on licenced indications (in 2019) 142 -- 6.3.2 Priority list « Hiérarchisation des indications des immunoglobulines humaines polyvalentes – Version Avril 2019 » 143 -- 6.4 CANADA 150 -- 6.4.1 Guideline development in Canadian Provinces and Territories 150 -- 6.4.2 Recommended indications for which there is consensus in all Provincial guidelines 151 -- 6.4.3 Indications for which Provincial guidelines have no consensus 152 -- 6.4.4 Not recommended indications per Provincial Guideline 155 -- 6.5 ENGLAND 157 -- 6.5.1 Colour-coding priority system of indications for Ig use in England 15